Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
Matthew WassermanJohnna E PerdrizetLindsay GrantKyla HayfordShubhra SinghParanjoy SahariaEmily K HornRaymond A FarkouhPublished in: Infectious diseases and therapy (2021)
Despite the success of PCV10 and PCV13 in reducing pneumococcal disease, a substantial clinical and economic burden remains due to serotypes contained in investigational vaccines.